Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation

AstraZeneca

Status: Completed

Conditions: Gastric Ulcer; Duodenal Ulcer

Study type: Observational

Funder types: Industry

Identifiers

NCT01562600

D961HC00012

Details and patient eligibility

About

The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with non-steroidal anti-inflammatory drug (NSAID).

Full description

Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with NSAIDs

Enrollment: 1,634 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients who are given NSAIDs for long terms to control pain due to disease such as rheumatoid arthritis and osteoarthritis, and given Nexium to suppress recurrence of gastric ulcer or duodenal ulcer.

Exclusion criteria

• Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of Sakita-Miwa classification on endoscopy)
• Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.

Trial design

1,634 participants in 1 patient group

Nexium